Aerovate Therapeutics Inc
NASDAQ:JBIO

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:JBIO
Watchlist
Price: 10.8 USD -0.41% Market Closed
Market Cap: 348.2m USD

Relative Value

There is not enough data to reliably calculate the relative value of JBIO.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JBIO Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.1
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-8.7
Industry
22.9
Forward
-4.2
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-10.8
Industry
19.4
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-10.7
Industry
22.6
vs History
70
vs Industry
61
Median 3Y
3.3
Median 5Y
3.1
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.2
vs History
19
vs Industry
29
Median 3Y
-4.9
Median 5Y
-5.8
Industry
4.5
vs History
19
vs Industry
27
Median 3Y
-4.9
Median 5Y
-5.8
Industry
4.5
Forward
0.1
vs History
19
vs Industry
30
Median 3Y
-6.4
Median 5Y
-6.7
Industry
5
vs History
19
vs Industry
26
Median 3Y
-6.3
Median 5Y
-6.7
Industry
3.7
vs History
vs Industry
2
Median 3Y
144.4
Median 5Y
145.2
Industry
4.9

Multiples Across Competitors

JBIO Competitors Multiples
Aerovate Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
75.7m USD 0 -1.1 0 0
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 615 484 -159 769.4 -194 011 -191 797.1
US
Abbvie Inc
NYSE:ABBV
336.9B USD 5.9 81.1 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
159.6B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
138.8B USD 4.8 23.3 10.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.4B USD 10.6 -118.8 25.2 26.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 095.7 -534.8 -582.3 -566.8
AU
CSL Ltd
ASX:CSL
116.7B AUD 5 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.3B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.9 -66.7 -60.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43B USD 18.3 -159.3 -715.5 -358.5
P/S Multiple
Revenue Growth P/S to Growth
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
Average P/S: 3 361 765.3
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 615 484
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 095.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.3
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
Average P/E: 34.5
Negative Multiple: -1.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 769.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -118.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.8 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -159.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
Average EV/EBITDA: 13.5
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 011 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -582.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -715.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
Average EV/EBIT: 17.4
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 797.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -358.5 N/A N/A